MYB anticorps (AA 119-135)

N° du produit ABIN6940143

Détail du produit anti-MYB anticorps

Antigène: MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))

Épitope: AA 119-135

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp MYB est non-conjugé

Application: ELISA, Coating (Coat)

Purification: Purified by Protein A/G

Immunogène: A synthetic peptide, corresponding to aa 119-135 (RRKVEQEGYPQESSKAG) of c-myb onco protein, coupled to KLH

Clone: MYB286

Isotype: IgG1 kappa

Information d'application

Indications d'application:

Positive Control: Jurkat, MOLT-4, COLO or BT-20 cells. Colon or breast carcinomas.

Known Application: ELISA (Use Ab at 2-4 μg/mL for coating) (Order Ab without BSA), Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Stockage

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-80 °C

Stockage commentaire: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Date de péremption: 24 months

Détails sur MYB

Antigène: MYB (V-Myb Myeloblastosis Viral Oncogene Homolog (Avian) (MYB))

Autre désignation: MYB (MYB Produits)

Synonymes: anticorps Cmyb, anticorps c-myb, anticorps c-myb_CDS, anticorps efg, anticorps AI550390, anticorps M16449, anticorps cmyb, anticorps xmyb, anticorps MYB proto-oncogene, transcription factor, anticorps myeloblastosis oncogene, anticorps MYB proto-oncogene, transcription factor S homeolog, anticorps v-myb avian myeloblastosis viral oncogene homolog, anticorps MYB, anticorps Myb, anticorps myb.S, anticorps myb

Sujet: The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.

Poids moléculaire: ~75kDa

ID gène: 4602

UniProt: P01104

Pathways: Chromatin Binding, Positive Regulation of Immune Effector Process